Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Prognostic Impact of Regulatory T-cells in Predicting Response and Prognosis in Primary Breast Cancer


Affiliations
1 Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Minia University, Egypt
2 Pathology Department, Faculty of Medicine, Minia University, Egypt
     

   Subscribe/Renew Journal


Background: The role of tumor-infiltrating lymphocytes (TILs) in breast cancer has been extensively studied over the last decade; it now believed that they have predictive and prognostic roles in breast cancer. Materials and Method: We identified 70 patients with primary breast cancers receiving neoadjuvant chemotherapy (NAC); we analyzed pre-and post-treatment tumor-infiltrating immune cells (CD3, CD8) by immunohistochemistry. Immune cell profiles were analyzed and correlated with response and survival. Results: We identified two tumor-infiltrating immune cell profiles, which were able to predict pathological complete response (pCR) to NAC. A higher infiltration by CD8 and CD3 lymphocytes was associated with occurrence of pCR. Analysis of the immune infiltrate in post-chemotherapy treatment identified a profile of high CD8 and low CD3 infiltration associated with better disease free survival. Conclusions: Tumor lymphocytic infiltrates play a predictive role for detecting pCR and a prognostic role in detecting the outcome. Further understanding of the mechanisms underlying the distribution of immune cells and their changes after chemotherapy may contribute to the development of new immune-targeted therapies for breast cancer.

Keywords

Tumor lymphocytic; chemotherapy; neoadjuvant
Subscription Login to verify subscription
User
Notifications
Font Size


Abstract Views: 74

PDF Views: 0




  • Prognostic Impact of Regulatory T-cells in Predicting Response and Prognosis in Primary Breast Cancer

Abstract Views: 74  |  PDF Views: 0

Authors

Nada Hussein Ali Sholkamy
Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Minia University, Egypt
Wafaa Mohamed Abd El-Latif
Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Minia University, Egypt
Mohamed Ahmed Hassen
Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Minia University, Egypt
Amani Saber Guirguis
Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Minia University, Egypt
Marian Fathi Kamal
Pathology Department, Faculty of Medicine, Minia University, Egypt
Amrou Mamdouh Abdein Shaaban
Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Minia University, Egypt
Hoda Mohktar Abdel Azeem
Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Minia University, Egypt

Abstract


Background: The role of tumor-infiltrating lymphocytes (TILs) in breast cancer has been extensively studied over the last decade; it now believed that they have predictive and prognostic roles in breast cancer. Materials and Method: We identified 70 patients with primary breast cancers receiving neoadjuvant chemotherapy (NAC); we analyzed pre-and post-treatment tumor-infiltrating immune cells (CD3, CD8) by immunohistochemistry. Immune cell profiles were analyzed and correlated with response and survival. Results: We identified two tumor-infiltrating immune cell profiles, which were able to predict pathological complete response (pCR) to NAC. A higher infiltration by CD8 and CD3 lymphocytes was associated with occurrence of pCR. Analysis of the immune infiltrate in post-chemotherapy treatment identified a profile of high CD8 and low CD3 infiltration associated with better disease free survival. Conclusions: Tumor lymphocytic infiltrates play a predictive role for detecting pCR and a prognostic role in detecting the outcome. Further understanding of the mechanisms underlying the distribution of immune cells and their changes after chemotherapy may contribute to the development of new immune-targeted therapies for breast cancer.

Keywords


Tumor lymphocytic; chemotherapy; neoadjuvant



DOI: https://doi.org/10.37506/v11%2Fi2%2F2020%2Fijphrd%2F195019